Phase 2Completed
Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients
A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients
- Sponsor
- Valneva Austria GmbH (Industry)
- Enrollment
- 400 enrolled
- Conditions
- Pneumonia, Ventilator-Associated
- Interventions
- IC43; Placebo
- Ages
- adults, older adults
- Registry
- NCT00876252
Full record on ClinicalTrials.gov
From the registry
Randomized, placebo-controlled, partially blinded phase 2 pilot study. Multicenter study (approximately 50 centers) in approximately 9 countries. Proposed start date is December 2008. The study duration per patient is estimated to be 90 days. Overall study duration is estimated to be 12-18 months.
Primary outcomes
- Immunogenicity at day 14 as determined by OprF/I specific IgG antibody titer measured by ELISA in patients receiving IC43 or placebo
History
Last registry update
Primary completion
Registered
Started